Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry

Digestive and Liver Disease

Volumn 42, Issue 9, 2010, Pages 597-605

  Del Chiaro, Marco ^a   Zerbi, Alessandro ^b   Capurso, Gabriele ^c   Zamboni, Giuseppe ^d   Maisonneuve, Patrick ^e   Presciuttini, Silvano ^f   Arcidiacono, Paolo Giorgio ^g   Calculli, Lucia ^h   Falconi, Massimo ^d  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Family history; Pancreas; Surveillance protocol

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; FAMILY HISTORY; HUMAN; ITALY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 77955269404     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.04.016     Document Type: Article

References (122)

1. Sperti C., Pasquali C., Piccoli A., Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996, 83:625-631.
2. Zanetti R., Buiatti E., Federico M., Micheli A. Fatti e Cifre dei Tumori in Italia. 1a Edizione 1998, Il Pensiero Scientifico Editore, Rome, Italy, pp. 9-29.
3. Del Chiaro M., Zerbi A., Falconi M., et al. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 2007, 7:459-469.
4. Iodice S., Gandini S., Maisonneuve P., Lowenfels A.B. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langebecks Arch Surg 2008, 393:535-545.
5. Mulder I., Hoogenveen R.T., van Genugten M.L. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol 2002, 14:1343-1353.
6. McWilliams R.R., Bamlet W.R., Rabe K.G., et al. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol 2006, 4:1143-1147.
7. Brand R.E., Greer J.B., Zolotarevsky E., et al. Pancreatic Cancer Patients Who Smoke and Drink are Diagnosed at Younger Ages. Clin Gastroenterol Hepatol 2009, [Epub ahead of print] PubMed PMID: 19560558.
8. Rulyak S.J., Lowenfels A.B., Maisonneuve P., Brentnall T.A. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124:1292-1299.
9. Howes N., Lerch M.M., Greenhalf W., et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004, 2:252-261.
10. Talamini G., Falconi M., Bassi C., et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999, 92:1253-1260.
11. Hassan M.M., Bondy M.L., Wolff R.A., et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007, 102:1-12.
12. Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132:2208-2225.
13. Larsson S.C., Orsini N., Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 2007, 120:1993-1998.
14. Berrington de Gonzalez A., Sweetland S., Spencer E. A meta-analysis of obesity and the risk of pancreatic caner. Br J Cancer 2003, 89:519-523.
15. Pezzilli R., Morselli-Labate A.M., Migliori M., et al. Obesity and the risk of pancreatic cancer: an Italian multicenter study. Pancreas 2005, 31:221-224.
16. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
17. Li D., Morris J.S., Liu J., et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. J Am Med Assoc 2009, 301:2553-2562.
18. Jiao L., Silverman D.T., Schairer C., et al. Alcohol Use and Risk of Pancreatic Cancer. The NIH-AARP Diet and Health Study. Am J Epidemiol 2009.
19. Genkinger J.M., Spiegelman D., Anderson K.E., et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 2009, 18:765-776.
20. Anderson K.E., Sinha R., Kulldorff M., et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 2002, 506/507:225-231.
21. Michaud D.S., Giovannucci E., Willett W.C., et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 2003, 157:1115-1125.
22. Jiao L., Mitrou P.N., Reedy J., et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med 2009, 169:764-770.
23. Stevens R.J., Roddam A.W., Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007, 96:507-509.
24. Huxley R., Ansare-Moghaddam A., Berrington de Gonzalez A., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
25. Pannala R., Basu A., Petersen G.M., Chari S.T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10:88-95.
26. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, [Epub ahead of print].
27. McKay C.J., Glen P., McMillan D.C. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008, 22:65-73.
28. Ojajärvi I.A., Partanen T.J., Ahlbom A., et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000, 57:316-324.
29. Stolzenberg-Solomon R.Z., Blaser M.J., Limburg P.J., et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 2001, 93:937-941.
30. de Martel C., Llosa A.E., Friedmana G.D., et al. Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:1188-1194.
31. Luo J., Nordenvall C., Nyrén O., et al. The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. Int J Cancer 2007, 120:368-377.
32. Capurso G., Delle Fave G., Lemoine N. Re: Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 2004, 96:75.
33. Gandini S., Lowenfels A.B., Jaffee E.M., et al. Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev 2005, 14:1908-1916.
34. Bjelakovic G., Nikolova D., Simonetti R.G., Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004, 364:1219-1228.
35. Larsson S.C., Giovannucci E., Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006, 131:1271-1283.
36. Bonovas S., Filioussi K., Sitaras N.M. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 2008, 103:2646-2651.
37. Capurso G., Schünemann H.J., Terrenato I., et al. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 2007, 26:1089-1099.
38. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64:2634-2638.
39. Evans J.P., Burke W., Chen R., et al. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 1995, 32:330-335.
40. Brentnall T.A., Bronner M.P., Byrd D.R., Haggitt R.C., Kimmey M.B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131:247-255.
41. Naderi A., Couch F.J. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002, 31:99-106.
42. Thompson D., Easton D.F. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94:1358-1365.
43. Lynch H.T., Voorhees G.J., Lanspa S.J., McGreevy P.S., Lynch J.F. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985, 52:271-273.
44. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218.
45. Watson P., Vasen H.F., Mecklin J.P., et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123:444-449.
46. Elkharwily A., Gottlieb K. The pancreas in familial adenomatous polyposis. JOP 2008, 9:9-18.
47. Giardiello F.M., Offerhaus G.J., Lee D.H., et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34:1394-1396.
48. Maisonneuve P., Marshall B.C., Lowenfels A.B. Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007, 56:1327-1328.
49. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89:442-446.
50. Howes N., Lerch M.M., Greenhalf W., et al. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004, 2:252-261.
51. Vasen H.F., Gruis N.A., Frants R.R., van Der Velden P.A., Hille E.T., Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000, 87:809-811.
52. Borg A., Sandberg T., Nilsson K., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92:1260-1266.
53. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high-risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447-1453.
54. van der Heijden M.S., Yeo C.J., Hruban R.H., Kern S.E. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63:2585-2588.
55. Couch F.J., Johnson M.R., Rabe K., et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005, 65:383-386.
56. Geoffroy-Perez B., Janin N., Ossian K., et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001, 93:288-293.
57. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362.
58. Hammel P.R., Vilgrain V., Terris B., et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000, 119:1087-1095.
59. Alexakis N., Connor S., Ghaneh P., et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004, 4:417-433.
60. Raimondi S., Maisonneuve P., Löhr J.M., Lowenfels A.B. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007, 16:1894-1897.
61. Lowenfels A.B., Maisonneuve P., Whitcomb D.C., Lerch M.M., DiMagno E.P. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. J Am Med Assoc 2001, 286:169-170.
62. Wang W., Chen S., Brune K.A., Hruban R.H., Parmigiani G., Klein A.P. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007, 25:1417-1422.
63. Hruban R.H., Pitman M.B., Klimstra D.S. Tumors of the pancreas. AFIP Atlas of tumor pathology, 6 vol. 2007, American Registry of Pathology, Armed Forces Institute of Pathology, Washington, DC.
64. Hruban R.H., Takaori K., Canto M., et al. Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg 2007, 14:255-263.
65. Hruban R.H., Takaori K., Klimstra D.S., et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004, 28:977-987.
66. Kim G.E., Bae H.I., Park H.U., et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002, 123:1052-1060.
67. Prasad N.B., Biankin A.V., Fukushima N., et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005, 65:1619-1626.
68. Maitra A., Adsay N.V., Argani P., et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003, 16:902-912.
69. Maitra A., Ashfaq R., Gunn C.R., et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002, 118:194-201.
70. Cubilla A.L., Fitzgerald P.J. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976, 36:2690-2698.
71. Andea A., Sarkar F., Adsay V.N. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003, 16:996-1006.
72. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006, 30:1067-1076.
73. Luttges J., Zamboni G., Longnecker D., Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001, 25:942-948.
74. Adsay N.V., Merati K., Basturk O., et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an " intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004, 28:839-848.
75. Yamaguchi T., Baba T., Ishihara T., et al. Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol 2005, 3:1136-1143.
76. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4:766-781. [quiz 665].
77. Su G.H., Hruban R.H., Bansal R.K., et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999, 154:1835-1840.
78. Maire F., Hammel P., Terris B., et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 2002, 51:446-449.
79. Zamboni G., Scarpa A., Bogina G., et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999, 23:410-422.
80. Zamboni G., Klöppel G., Hruban R., Longnecker D., Adler G. Mucinous cystic neoplasms of the pancreas 2000, IARC Press, Lyon, pp. 234-236.
81. Fukushima N., Sato N., Prasad N., Leach S.D., Hruban R.H., Goggins M. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 2004, 23:9042-9051.
82. Iacobuzio-Donahue C.A., Wilentz R.E., Argani P., et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000, 24:1544-1548.
83. Miller F.H., Rini N.J., Keppke A.L. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol 2006, 187:W365-W374.
84. Bipat S., Phoa S.S., van Delden O.M., et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005, 29:438-445.
85. Ichikawa T., Peterson M., Federle M., et al. Islet cell tumor of pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000, 216:163-171.
86. Nishiharu T., Yamashita Y., Abe Y., et al. Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging-ROC analysis. Radiology 1999, 212:445-452.
87. Sahani D.V., Shah Z.K., Catalano O.A., Boland G.W., Brugge W.R. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 2008, 23:23-33.
88. Mertz H., Sechopoulos P., Delbeke D., Leach S.D. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinomas. Gastrointest Endosc 2000, 52:367-371.
89. Legmann P., Vignaux O., Dousset B., Baraza A.J., Palazzo L., Dumontier I., et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonographic. Am J Roentgenol 1998, 170:1315-1322.
90. Raut C.P., Grau A.M., Staerkel G.A., et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003, 7:118-128.
91. Ariyama J., Suyama M., Satoh K., Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 1998, 16:396-401.
92. Hunt G.C., Faigel D.O. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc 2002, 55:232-237.
93. DeWitt J., Devereaux B., Chriswell M., et al. Comparison of endoscopic ultrasonography and multidetector computer tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004, 141:753-763.
94. Agarwal B., Abu-Hamda E., Molke K.L., Correa A.M., HO L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004, 99:844-850.
95. Chang K.J., Nguyen P., Erickson R.A., Durbin T.E., Katz K.D. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997, 45:387-393.
96. Farrow B., Sugiyama Y., Chen A., Uffort E., Nealon W., Evers B.M. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004, 239:763-771.
97. Rulyak S.J., Kimmey M.B., Veenstra D.L., Brentnall T.A. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57:23-29.
98. Adler D.G., Jacobson B.C., Davila R.E., et al. Faigel DO ASGE guideline: complications of EUS. Gastrointest Endosc 2005, 61:8-12.
99. Fernández-Esparrach G., Ginès A., García P., et al. Incidence and clinical significance of hyperamylasemia after endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of pancreatic lesions: a prospective and controlled study. Endoscopy 2007, 39:720-724.
100. Gress F., Michael H., Gelrud D., et al. EUS guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc 2002, 56:864-867.
101. O'Toole D., Palazzo L., Arotcarena R., et al. Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest Endosc 2001, 53:470-474.
102. Al-Haddad M., Wallace M.B., Woodward T.A., et al. The safety of fine-needle aspiration guided by endoscopic ultrasound: a prospective study. Endoscopy 2008, 40:204-208.
103. Affi A., Vazquez-Sequeiros E., Norton I., Clain J., Wiersema M. Acute extraluminal hemorrhage associated with EUS-guided fine needle aspiration: Frequency and clinical significance. Gastrointest Endosc 2001, 53:221-225.
104. Eloubeidi M., Tamhane A., Varadarajulu S., Wilcox C. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc 2006, 63:622-629.
105. Eloubeidi M.A., Chen V.K., Eltoum I.A., et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol 2003, 98:2663-2668.
106. Varadarajulu S., Eloubeidi M.A. Frequency and significance of acute intracystic hemorrhage during EUS-FNA of cystic lesions of the pancreas. Gastrointest Endosc 2004, 60:631-635.
107. Levy M.J., Norton I.D., Wiersema M.J., et al. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. Gastrointest Endosc 2003, 57:672-678.
108. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas, 201 patients. Ann Surg 1995, 221:721-731.
109. Malesci A., Montorsi M., Mariani A., et al. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992, 7:497-502.
110. Kimmey M.B., Brentnall T.A., Bronner M.P., et al. Endoscopic ultrasound screening for familial pancreatic cancer. Gastrointest Endosc 2002, 56:S82-S86.
111. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in highrisk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2:606-621.
112. Jorgensen M.T., Mortensen M.B., Gerdes A.M., Schaffalitzky De Muckadell O.B. Familial pancreatic cancer. Scand J Gastroenterol 2008, 43:387-397.
113. Brand R.E., Lerch M.M., Rubinstein W.S., et al. Advances in Counseling and Surveillance of Patients at Risk for Pancreatic Cancer. Gut 2007, 56:1460-1469.
114. McFaul C., Greenhalf W., Earl J., et al. Anticipation in familial pancreatic cancer. Gut 2006, 55:252-258.
115. Singh M., Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007, 7:9-19. Epub 2007 April 18.
116. White R., D'Angelica M., Katabi N., et al. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg 2007, 204:987-993. discussion 993-5. Epub 2007 Mar 27.
117. Kekis P.B., Friess H., Kleeff J., Büchler M.W. Timing and extent of surgical intervention in patients from hereditary pancreatic cancer kindreds. Pancreatology 2001, 1:525-530.
118. Rulyak S.J., Brentnall T.A. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001, 1:477-485. [review].
119. Davis B., Lowy A.M. Surgical management of hereditary pancreatic cancer. Med Clin North Am 2000, 84:749-759. [review. Department of Surgery, University of Cincinnati College of Medicine, OH, USA].
120. Charpentier K.P., Brentnall T.A., Bronner M.P., Byrd D., Marsh C. A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin Transplant 2004, 18:105-107.
121. Steinberg W.M., Barkin J.S., Bradley E.L., et al. Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas?. Pancreas 2009, 38:e137-e150.
122. Partelli S., Castillo C.F., Bassi C., et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg 2010, 251:477-482.